



MHRA Strategy to 2030: What it means for healthcare professionals

Doctors, nurses, pharmacists and other clinicians make decisions every day about the safe and effective use of medicines and medical devices. Our strategy aims to support those decisions with clearer regulatory information, better use of evidence generated from routine care and earlier identification of safety concerns.

As innovative medicines and AI-enabled medical devices enter clinical practice, we will maintain robust standards while adapting how we assess and monitor them. The National Commission into the Regulation of AI in Healthcare is one example of how we are working with partners, including healthcare professionals, to support safe deployment. Real-world evidence and AI-enabled tools will complement and not replace expert scientific and clinical judgement.

Your experience is essential to understanding how products perform beyond clinical trials. Reporting suspected adverse reactions or device incidents, sharing clinical insight and highlighting differences in outcomes between patient groups can help us identify emerging risks and take more targeted action. Your input will also inform our new benefit-risk framework and improvements to regulatory and product information.

Supporting clinical practice across the product lifecycle

Our priority What it means for healthcare professionals

Continuous safety monitoring

We will work with the Health Data Research Service (HDRS) to support more active and real-time safety monitoring. Better use of linked health data, real-world evidence and AI-enabled tools will help identify emerging safety signals earlier and inform more targeted action.

Simpler safety reporting

From 2027, we will begin introducing a more conversational Yellow Card reporting interface. We will also explore integration with the NHS App and major secondary care electronic health record systems, complementing existing primary care functionality.

Clearer regulatory evidence

By 2027, we will publish a benefit-risk framework, developed with patients and clinicians, explaining how we assess evidence and make regulatory decisions. This will support informed clinical judgement and better conversations with patients about treatment options.

Accessible product information

By 2030, we aim to make all product information available as structured digital content. This will make information about indications, benefits, risks and emerging safety evidence easier to access and use, while retaining alternative formats for those who need them.

Safe adoption of innovation

We will work with the NHS, NICE and other partners to align evidence requirements and support readiness for new medicines and technologies. Through closer alignment between MHRA licensing and NICE value assessment, some medicines could reach patients **three to six months earlier** than before.

